New York Times Columnist Ron Lieber discusses his book "The Price You Pay for College."

Host: Carol Massar. Producer: Doni Holloway.

New York Times Columnist Ron Lieber discusses his book "The Price You Pay for College."Host: Carol Massar. Producer: Doni Holloway.

Listen for reporting from the magazine that helps global leaders stay ahead. Hosts Carol Massar and Tim Stenovec cover the changing world of money, power and technology. You can watch and listen to Businessweek LIVE on YouTube, weekdays from 2PM to 5PM ET: http://bit.ly/3vTiACF. 

Listen for reporting from the magazine that helps global leaders stay ahead. Hosts Carol Massar and Tim Stenovec cover the changing world of money, power and technology.&nbsp;You can watch and listen to Businessweek LIVE on YouTube, weekdays from 2PM to 5PM ET:&nbsp;<a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.&nbsp;

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more by harnessing the power of Bloomberg Businessweek reporters and editors.

Bloomberg Businessweek

Lieber on New Book

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/3843d2e5-de33-4973-8f38-ae2b0046decc/transcript

The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF. 

On this episode of Bloomberg Businessweek Daily, hosts Carol Massar and Tim Stenovec speak with Bill Rauch and Zhailon Levingston, co-directors of 'Cats: The Jellice Ball' about their newly reimaging and relaunching of the beloved Broadway musical. 

The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.&nbsp;
On this episode of Bloomberg Businessweek Daily, hosts Carol Massar and Tim Stenovec speak with Bill Rauch and Zhailon Levingston, co-directors of 'Cats: The Jellice Ball' about their newly reimaging and relaunching of the beloved Broadway musical.&nbsp;

'Cats: The Jellicle Ball' Co-Directors Bill Rauch & Zhailon Levingston 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/949771db-18fb-419e-b0c6-b44701617fe1/transcript

The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF. 
On this episode of Bloomberg Businessweek Daily, hosts Carol Massar and Tim Stenovec speak with:
Jeff Kip, CEO of Angi on the company's latest earnings, AI efforts and its outlook on the housing market.
Denise Paulonis, Sally Beauty CEO and President on her company's results, why she thinks lower-end consumers are feeling pressure, and the company's TikTok and social media e-commerce strategies.
Amara Omeokwe, Bloomberg News Federal Reserve reporter on her Big Take and Businessweek feature: Powell Exits With Legacy Built on Central Bank Independence

The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: <a href="http://bit.ly/3vTiACF" data-destination="rte:bind">http://bit.ly/3vTiACF</a>. On this episode of Bloomberg Businessweek Daily, hosts Carol Massar and Tim Stenovec speak with:
<ul>
<li>Jeff Kip, CEO of Angi on the company's latest earnings, AI efforts and its outlook on the housing market.</li>
<li>Denise Paulonis, Sally Beauty CEO and President on her company's results, why she thinks lower-end consumers are feeling pressure, and the company's TikTok and social media e-commerce strategies.</li>
<li>Amara Omeokwe, Bloomberg News Federal Reserve reporter on her Big Take and Businessweek feature: <a data-destination="bb:NSN TEUATXKGIFRO">Powell Exits With Legacy Built on Central Bank Independence</a></li>
</ul>

Angi CEO Jeff Kip & Sally Beauty CEO Denise Paulonis on Earnings 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/cf6da9c7-ce86-4cf6-85fd-b447015e006b/transcript

Blackstone Life Sciences, which has some $17 billion in assets under management, typically invests in late-stage medicines invented by biotech and pharmaceutical companies in exchange for a royalty on future sales. In 2024, for example, the firm invested as much as $750 million in financing for Moderna’s flu vaccine development.

But Blackstone also wants to own a stake in some companies that it backs. 
In late March, Blackstone closed its latest life-sciences fund with $6.3 billion of commitments, the firm’s biggest haul for backing clinical trials of medicines and technologies. 

Dr. Jenny Rooke is Founder and Managing Director of Genoa Ventures. She discusses the cross between tech and health with Carol Massar and Tim Stenovec.

Blackstone Life Sciences, which has some $17 billion in assets under management, typically invests in late-stage medicines invented by biotech and pharmaceutical companies in exchange for a royalty on future sales. In 2024, for example, the firm invested as much as $750 million in financing for Moderna&rsquo;s flu vaccine development. But Blackstone also wants to own a stake in some companies that it backs. In late March, Blackstone closed its latest life-sciences fund with $6.3 billion of commitments, the firm&rsquo;s biggest haul for backing clinical trials of medicines and technologies.&nbsp; Dr. Jenny Rooke is Founder and Managing Director of Genoa Ventures. She discusses the cross between tech and health with Carol Massar and Tim Stenovec.

Investing in Life Sciences

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/bff6d8f0-2d30-433d-9752-b444015e5d1a/transcript

Lieber on New Book

In 1 playlist(s)

Bloomberg Businessweek

Social links

Follow podcast

Recent clips